Y-mAbs Therapeutics

Create an alert
to follow the executive moves at Y-mAbs Therapeutics.

Y-mAbs Therapeutics is one of the...

• Russell 3000.

Most searched biographies at Y-mAbs Therapeutics

• Claus Moeller, Chief Executive Officer and Director
• Gerard Ber, Director
• Johan Wedell-Wedellsborg, Director

Click on an executive to view his biography >

Latest M&A news in Biotechnology.

Bio-Techne has acquired Asuragen (posted on Apr 7, 2021).
EQT has announced the acquisition of Cerba Healthcare (posted on Apr 1, 2021).
Everlywell has announced the acquisition of PWNHealth (posted on Mar 26, 2021).

Other contacts in the Biotechnology industry

• Tal Zaks - Non-Executive Director at Adaptimmune Therapeutics
• John Dunn - Director at Acer Therapeutics
• Adam Stern - Director at Matinas BioPharma

Learn more about the Biotechnology industry >

Latest news about Y-mAbs Therapeutics

Y-mAbs Therapeutics to Present At 39th Annual J.P. Morgan Healthcare Conference | Y-mAbs Therapeutics, Inc.
Y-mAbs Announces Sale of Priority Review Voucher | Y-mAbs Therapeutics, Inc.
Press Releases | Y-mAbs Therapeutics, Inc.
Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk) and Omburtamab in Eastern Europe | Y-mAbs Therapeutics, Inc.
Y-mAbs Signs License Agreement with SciClone for DANYELZA® (naxitamab-gqgk) and Omburtamab in China | Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics on Wikipedia, Google News & Yahoo Finance

Y-mAbs Therapeutics on LinkedIn, Twitter & YouTube

Y-mAbs Therapeutics has 1,630 competitors including Biogen (United States (USA)), Eurofins (France) and Neptune Wellness Solutions (Canada).

Call Y-mAbs Therapeutics at +1 646....

View the org chart

Register to receive your alert

Report an error